To obtain the subject medicine having activities for decreasing fat in hepatocytes, hardly providing anxiety to side effects, capable of being administered for a long term, and useful for improvement of fatty liver by including a specific galactooligosaccharide sulfate.
This improver of hepatic damage contains a galactooligosaccharide sulfate of formulas I or II. The compound of formulas I or II is obtained, for example, by culturing microorganisms [e.g. S-22 belonging to the genus Arthrobacter (FERM P-15496)] having degrading activities against porphyran which is polysaccharides of a seaweed belonging to the genus Porphyra, in a liquid medium containing powder or the like of the seaweed belonging to the genus Porphyra, and obtained by adding a carbon source such as lactose, a nitrogen source such as peptone, or the like thereto, preferably at 20-30°C culturing temperature at 4-8 culturing pH value under an aerobic condition for 2-5 days to hydrolyze the phycobiont of the seaweed belonging to the genus Porphyra, especially porphyran, and removing impurities such as a protein from the cultured medium. The daily dose of the compound of formulas I or II is preferably 3-10 mg.
MORIYA KAZUHITO
SASAZUKA TADASHI
HOKKAIDO SUGAR CO
Next Patent: MEDICINE CONTAINING SULODEXIDE FOR TREATMENT OF DIABETIC RETINOPATHY